New opioid may have less potential for abuse

The immediate-release form of the drug, which inhibits the uptake of noradrenaline, is indicated for moderate to severe pain, but a sustained release form is also approved in Australia for moderate chronic pain unresponsive to non-narcotic analgesia.

An Australian Prescriber review stated that a trial revealed the analgesic effect of tapentadol (100mg) was comparable to oxycodone (15mg), with increased somnolence but reduced incidence of nausea and vomiting.

The review concluded: “The efficacy appears to be similar to